H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Paratek Pharmaceuticals to $10 from $20 and keeps a Buy rating on the shares post the Q4 results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
- Paratek Pharmaceuticals sees FY23 revenue $143M-$158M, consensus $232.02M
- Paratek Pharmaceuticals reports Q4 EPS (13c), consensus 9c
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
- Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue